SCIENTIA SINICA Vitae, Volume 50 , Issue 8 : 802-811(2020) https://doi.org/10.1360/SSV-2020-0119

Scientific basis and feasibility of exploring mesenchymal stem cells for the treatment of Coronavirus disease 2019

More info
  • ReceivedApr 7, 2020
  • AcceptedMay 18, 2020
  • PublishedMay 21, 2020


Since the outbreak of Coronavirus disease 2019 (COVID-19), researchers have been proposing new treatment regimes. However, there is no specific treatment or drug for COVID-19. Mesenchymal stem cells (MSCs) are a class of multipotent tissue stem cells with immunoregulatory and tissue repair functions. Several studies using MSCs for the treatment of acute lung injury, severe pneumonia, and acute respiratory distress syndrome have shown safety and effectiveness. Domestic and foreign clinical trials using MSCs to treat COVID-19 have been approved and filed, which are underway. Considering the pathological characteristics of COVID-19, discussing the scientific basis and feasibility of MSCs treatment may explore the potential values of MSCs for the treatment of COVID-19.

Funded by




[1] Gorbalenya A E, Baker S C, Baric R S, et al. Severe acute respiratory syndrome-related coronavirus: The species and its viruses—A statement of the Coronavirus Study Group. bioRxiv, 2020, doi: 10.1101/2020.02.07.937862. Google Scholar

[2] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, 395: 497-506 CrossRef Google Scholar

[3] Zhang J, Zhou L, Yang Y, et al. Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics. Lancet Respir Med, 2020, 8: e11-e12 CrossRef Google Scholar

[4] Yin X, Hu L, Zhang Y, et al. PDGFB-expressing mesenchymal stem cells improve human hematopoietic stem cell engraftment in immunodeficient mice. Bone Marrow Transplant, 2019, doi: 10.1038/s41409-019-0766-z CrossRef PubMed Google Scholar

[5] Xia C, Wang T, Cheng H, et al. Mesenchymal stem cells suppress leukemia via macrophage-mediated functional restoration of bone marrow microenvironment. Leukemia, 2020, doi: 10.1038/s41375-020-0775-3 CrossRef PubMed Google Scholar

[6] Wang Y, Chen X, Cao W, et al. Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat Immunol, 2014, 15: 1009-1016 CrossRef PubMed Google Scholar

[7] Lee J W, Fang X, Krasnodembskaya A, et al. Concise review: Mesenchymal stem cells for acute lung injury: role of paracrine soluble factors. Stem Cells, 2011, 29: 913-919 CrossRef PubMed Google Scholar

[8] Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med, 2020, 8: 420-422 CrossRef Google Scholar

[9] Simonson O E, Mougiakakos D, Heldring N, et al. In vivo effects of mesenchymal stromal cells in two patients with severe acute respiratory distress syndrome. Stem Cells Transl Med, 2016, 5: 845 CrossRef PubMed Google Scholar

[10] Wilson J G, Liu K D, Zhuo H, et al. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med, 2015, 3: 24-32 CrossRef Google Scholar

[11] Matthay M A, Calfee C S, Zhuo H, et al. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. Lancet Respir Med, 2019, 7: 154-162 CrossRef Google Scholar

[12] Liu J, Li S, Liu J, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. medRxiv, 2020, doi: 10.1101/2020.02.16.20023671. Google Scholar

[13] López-Beas J, Guadix J A, Clares B, et al. An overview of international regulatory frameworks for mesenchymal stromal cell-based medicinal products: From laboratory to patient. Med Res Rev, 2020, doi: 10.1002/med.21659 CrossRef PubMed Google Scholar

[14] Wang D, Zhang H, Liang J, et al. A long-term follow-up study of allogeneic mesenchymal stem/stromal cell transplantation in patients with drug-resistant systemic lupus erythematosus. Stem Cell Rep, 2018, 10: 933-941 CrossRef PubMed Google Scholar

[15] Shi Y, Wang Y, Li Q, et al. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nat Rev Nephrol, 2018, 14: 493-507 CrossRef PubMed Google Scholar

[16] Willis G R, Fernandez-Gonzalez A, Anastas J, et al. Mesenchymal stromal cell exosomes ameliorate experimental bronchopulmonary dysplasia and restore lung function through macrophage immunomodulation. Am J Respir Crit Care Med, 2018, 197: 104-116 CrossRef PubMed Google Scholar

[17] Li N, Hua J. Interactions between mesenchymal stem cells and the immune system. Cell Mol Life Sci, 2017, 74: 2345-2360 CrossRef PubMed Google Scholar

[18] Uccelli A, de Rosbo N K. The immunomodulatory function of mesenchymal stem cells: mode of action and pathways. Ann NY Acad Sci, 2015, 1351: 114-126 CrossRef PubMed ADS Google Scholar

[19] Glennie S, Soeiro I ̂, Dyson P J, et al. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood, 2005, 105: 2821-2827 CrossRef PubMed Google Scholar

[20] Luz-Crawford P, Kurte M, Bravo-Alegría J, et al. Mesenchymal stem cells generate a CD4+CD25+Foxp3+ regulatory T cell population during the differentiation process of Th1 and Th17 cells. Stem Cell Res Ther, 2013, 4: 65 CrossRef PubMed Google Scholar

[21] Chen Q H, Wu F, Liu L, et al. Mesenchymal stem cells regulate the Th17/Treg cell balance partly through hepatocyte growth factor in vitro. Stem Cell Res Ther, 2020, 11: 91 CrossRef PubMed Google Scholar

[22] Luz-Crawford P, Hernandez J, Djouad F, et al. Mesenchymal stem cell repression of Th17 cells is triggered by mitochondrial transfer. Stem Cell Res Ther, 2019, 10: 232 CrossRef PubMed Google Scholar

[23] Corcione A, Benvenuto F, Ferretti E, et al. Human mesenchymal stem cells modulate B-cell functions. Blood, 2006, 107: 367-372 CrossRef PubMed Google Scholar

[24] Cho K A, Lee J K, Kim Y H, et al. Mesenchymal stem cells ameliorate B-cell-mediated immune responses and increase IL-10-expressing regulatory B cells in an EBI3-dependent manner. Cell Mol Immunol, 2017, 14: 895-908 CrossRef PubMed Google Scholar

[25] Franquesa M, Mensah F K, Huizinga R, et al. Human adipose tissue-derived mesenchymal stem cells abrogate plasmablast formation and induce regulatory B cells independently of T helper cells. Stem Cells, 2015, 33: 880-891 CrossRef PubMed Google Scholar

[26] de Witte S F H, Luk F, Sierra Parraga J M, et al. Immunomodulation by therapeutic mesenchymal stromal cells (MSC) is triggered through phagocytosis of MSC By monocytic cells. Stem Cells, 2018, 36: 602-615 CrossRef PubMed Google Scholar

[27] Reis M, Mavin E, Nicholson L, et al. Mesenchymal stromal cell-derived extracellular vesicles attenuate dendritic cell maturation and function. Front Immunol, 2018, 9 CrossRef PubMed Google Scholar

[28] Prockop D J. Concise review: two negative feedback loops place mesenchymal stem/stromal cells at the center of early regulators of inflammation. Stem Cells, 2013, 31: 2042-2046 CrossRef PubMed Google Scholar

[29] Lu Z, Chang W, Meng S, et al. Mesenchymal stem cells induce dendritic cell immune tolerance via paracrine hepatocyte growth factor to alleviate acute lung injury. Stem Cell Res Ther, 2019, 10: 372 CrossRef PubMed Google Scholar

[30] Johnson C L, Soeder Y, Dahlke M H. Concise review: Mesenchymal stromal cell-based approaches for the treatment of acute respiratory distress and sepsis syndromes. Stem Cells Transl Med, 2017, 6: 1141-1151 CrossRef PubMed Google Scholar

[31] Park K S, Svennerholm K, Shelke G V, et al. Mesenchymal stromal cell-derived nanovesicles ameliorate bacterial outer membrane vesicle-induced sepsis via IL-10. Stem Cell Res Ther, 2019, 10: 231 CrossRef PubMed Google Scholar

[32] Wang X, Wong K, Ouyang W, et al. Targeting IL-10 family cytokines for the treatment of human diseases. Cold Spring Harb Perspect Biol, 2019, 11: a028548 CrossRef PubMed Google Scholar

[33] Galleu A, Riffo-Vasquez Y, Trento C, et al. Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation. Sci Transl Med, 2017, 9: eaam7828 CrossRef PubMed ADS Google Scholar

[34] Sun M L, Yang J M, Sun Y P, et al. Inhibitors of RAS might be a good choice for the therapy of COVID-19 pneumonia (in Chinese). Chin J Tuberc Respir Dis, 2020, 43: E014 [孙美丽, 杨建民, 孙玉萍, 等. RAS抑制剂是治疗新型冠状病毒肺炎的可能选择之一. 中华结核和呼吸杂志, 2020,43: E014]. Google Scholar

[35] Leng Z, Zhu R, Hou W. Transplantation of ACE2 mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis, 2020, 11: 216–228. Google Scholar

[36] Chousterman B G, Swirski F K, Weber G F. Cytokine storm and sepsis disease pathogenesis. Semin Immunopathol, 2017, 39: 517-528 CrossRef PubMed Google Scholar

[37] Chen X, Zhao B, Qu Y, et al. Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely associated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients. medRxiv, 2020, doi: 10.1101/2020.02.29.20029520. Google Scholar

[38] Guo G, Zhuang X, Xu Q, et al. Peripheral infusion of human umbilical cord mesenchymal stem cells rescues acute liver failure lethality in monkeys. Stem Cell Res Ther, 2019, 10: 84 CrossRef PubMed Google Scholar

[39] Shao M, Xu Q, Wu Z, et al. Exosomes derived from human umbilical cord mesenchymal stem cells ameliorate IL-6-induced acute liver injury through miR-455-3p. Stem Cell Res Ther, 2020, 11: 37 CrossRef PubMed Google Scholar

[40] Gong Y, Shi Z X, Chen J, et al. Disease briefing: Coronaviruses (in Chinese). China Biotechnol, 2020, Z1: 1–20 [巩玥, 史志祥, 陈菁, 等. 冠状病毒的研究现状. 中国生物工程杂志, 2020, 2020, Z1: 1–20]. Google Scholar

[41] Fang X, Neyrinck A P, Matthay M A, et al. Allogeneic human mesenchymal stem cells restore epithelial protein permeability in cultured human alveolar type II cells by secretion of angiopoietin-1. J Biol Chem, 2010, 285: 26211-26222 CrossRef PubMed Google Scholar

[42] Hu S, Park J, Liu A, et al. Mesenchymal stem cell microvesicles restore protein permeability across primary cultures of injured human lung microvascular endothelial cells. Stem Cells Transl Med, 2018, 7: 615-624 CrossRef PubMed Google Scholar

[43] Sinclair K A, Yerkovich S T, Hopkins P M A, et al. Characterization of intercellular communication and mitochondrial donation by mesenchymal stromal cells derived from the human lung. Stem Cell Res Ther, 2016, 7: 91 CrossRef PubMed Google Scholar

[44] Wang S, Mo M, Wang J, et al. Platelet-derived growth factor receptor beta identifies mesenchymal stem cells with enhanced engraftment to tissue injury and pro-angiogenic property. Cell Mol Life Sci, 2018, 75: 547-561 CrossRef PubMed Google Scholar

[45] Xu S, De Veirman K, De Becker A, et al. Mesenchymal stem cells in multiple myeloma: a therapeutical tool or target?. Leukemia, 2018, 32: 1500-1514 CrossRef PubMed Google Scholar

[46] Coppin L, Sokal E, Stéphenne X. Thrombogenic risk induced by intravascular mesenchymal stem cell therapy: Current status and future perspectives. Cells, 2019, 8: 1160 CrossRef PubMed Google Scholar

[47] Lopes-Pacheco M, Robba C, Rocco P R M, et al. Current understanding of the therapeutic benefits of mesenchymal stem cells in acute respiratory distress syndrome. Cell Biol Toxicol, 2020, 36: 83-102 CrossRef PubMed Google Scholar

[48] Monsel A, Zhu Y, Gennai S, et al. Therapeutic effects of human mesenchymal stem cell-derived microvesicles in severe pneumonia in mice. Am J Respir Crit Care Med, 2015, 192: 324-336 CrossRef PubMed Google Scholar

[49] Li J W, Wu X. Mesenchymal stem cells ameliorate LPS-induced acute lung injury through KGF promoting alveolar fluid clearance of alveolar type II cells. Eur Rev Med Pharmacol Sci, 2015, 19: 2368–2378. Google Scholar

[50] Goolaerts A, Pellan-Randrianarison N, Larghero J, et al. Conditioned media from mesenchymal stromal cells restore sodium transport and preserve epithelial permeability in an in vitro model of acute alveolar injury. Am J Physiol-Lung Cell Mol Physiol, 2014, 306: L975-L985 CrossRef PubMed Google Scholar

[51] Nikolaidis N M, Noel J G, Pitstick L B, et al. Mitogenic stimulation accelerates influenza-induced mortality by increasing susceptibility of alveolar type II cells to infection. Proc Natl Acad Sci USA, 2017, 114: E6613-E6622 CrossRef PubMed Google Scholar

[52] Ito J T, Lourenço J D, Righetti R F, et al. Extracellular matrix component remodeling in respiratory diseases: What has been found in clinical and experimental studies?. Cells, 2019, 8: 342 CrossRef PubMed Google Scholar

[53] Kuhn H, Zobel C, Vollert G, et al. High amplitude stretching of ATII cells and fibroblasts results in profibrotic effects. Exp Lung Res, 2019, 45: 167-174 CrossRef PubMed Google Scholar

[54] Jiang X, Jiang X, Qu C, et al. Intravenous delivery of adipose-derived mesenchymal stromal cells attenuates acute radiation-induced lung injury in rats. Cytotherapy, 2015, 17: 560-570 CrossRef PubMed Google Scholar

[55] Srour N, Thébaud B. Mesenchymal stromal cells in animal bleomycin pulmonary fibrosis models: A systematic review. Stem Cells Transl Med, 2015, 4: 1500-1510 CrossRef PubMed Google Scholar

[56] Dong L, Pu Y, Chen X, et al. hUCMSC-extracellular vesicles downregulated hepatic stellate cell activation and reduced liver injury in S. japonicum-infected mice. Stem Cell Res Ther, 2020, 11: 21 CrossRef PubMed Google Scholar

[57] Viganò M, Lugano G, Perucca Orfei C, et al. Autologous microfragmented adipose tissue reduces the catabolic and fibrosis response in an in vitro model of tendon cell inflammation. Stem Cells Int, 2019, 2019: 1-10 CrossRef PubMed Google Scholar

[58] Antebi B, Mohammadipoor A, Batchinsky A I, et al. The promise of mesenchymal stem cell therapy for acute respiratory distress syndrome. J Trauma Acute Care Surg, 2018, 84: 183-191 CrossRef PubMed Google Scholar

[59] Krasnodembskaya A, Samarani G, Song Y, et al. Human mesenchymal stem cells reduce mortality and bacteremia in gram-negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes. Am J Physiol-Lung Cell Mol Physiol, 2012, 302: L1003-L1013 CrossRef PubMed Google Scholar

[60] Liang B, Chen J, Li T, et al. Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells. 2020, ChinaXiv:202002.00084. Google Scholar

[61] Yin J Q, Zhu J, Ankrum J A. Manufacturing of primed mesenchymal stromal cells for therapy. Nat Biomed Eng, 2019, 3: 90-104 CrossRef PubMed Google Scholar

[62] Patry C, Doniga T, Lenz F, et al. Increased mobilization of mesenchymal stem cells in patients with acute respiratory distress syndrome undergoing extracorporeal membrane oxygenation. PLoS ONE, 2020, 15: e0227460 CrossRef PubMed Google Scholar

[63] Huang R, Qin C, Wang J, et al. Differential effects of extracellular vesicles from aging and young mesenchymal stem cells in acute lung injury. Aging, 2019, 11: 7996-8014 CrossRef PubMed Google Scholar

[64] Moll G, Ankrum J A, Kamhieh-Milz J, et al. Intravascular mesenchymal stromal/stem cell therapy product diversification: Time for new clinical guidelines. Trends Mol Med, 2019, 25: 149-163 CrossRef PubMed Google Scholar

[65] Meng X, Su R J, Baylink D J, et al. Rapid and efficient reprogramming of human fetal and adult blood CD34+ cells into mesenchymal stem cells with a single factor. Cell Res, 2013, 23: 658-672 CrossRef PubMed Google Scholar

[66] Phinney D G, Pittenger M F. Concise review: MSC-derived exosomes for cell-free therapy. Stem Cells, 2017, 35: 851-858 CrossRef PubMed Google Scholar

[67] Phan J, Kumar P, Hao D, et al. Engineering mesenchymal stem cells to improve their exosome efficacy and yield for cell-free therapy. J Extracell Vesicles, 2018, 7: 1522236 CrossRef PubMed Google Scholar

Copyright 2020  CHINA SCIENCE PUBLISHING & MEDIA LTD.  中国科技出版传媒股份有限公司  版权所有

京ICP备14028887号-23       京公网安备11010102003388号